Leading the way for those left behind in pain


At Tremeau, we focus on well-defined patient populations with high unmet medical needs. Our unique approach to acute and chronic pain in select conditions is rooted in the mechanism of action, documented efficacy in painful inflammatory conditions, and clinically differentiated profile of COX-2 selective NSAIDs.

Tremeau believes that the multiple, often industry-independent, scientific evaluations of the past 15 years strongly suggest a re-examination of the potential utility of rofecoxib and etoricoxib. This is especially true with indications in which a COX-2 selective NSAID may provide therapeutic advantages over other standards of care, such as opioids.

TRM chartTRM chart

*The active ingredient in TRM-201 is rofecoxib, which was previously marketed as VIOXX®.
**The active ingredient in TRM-359 is etoricoxib, which was previously marketed outside the US as ARCOXIA.
ARCOXIA is a trademark of Tremeau Pharmaceuticals, Inc.
VIOXX is a registered trademark of Tremeau Pharmaceuticals, Inc.

Learn more about the TRM‑201 clinical trial
Father and Kids

Focusing on hemophilic arthropathy

Hemophilic arthropathy (HA) is a painful and debilitating joint disease that affects people with inheritable bleeding disorders. It is caused by recurrent intra-articular bleeding. HA is one of the most common complications encountered by patients with bleeding disorders, and is the largest cause of morbidity in patients with hemophilia.

There are currently no FDA-approved medications indicated to treat this type of joint pain, and opioids are the most frequently used prescription treatment.